Abstract：【Objective】To investigate the effect of Tirofiban on percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS).【Methods】A total of 100 patients with ACS who underwent PCI treatment in our hospital from March 2020 to March 2023 were selected and divided into observation group and control group according to random number table method, with 50 cases in each group. The control group was given routine treatment, the observation group was given intravenous tirofiban during PCI. TIMI blood flow grading, myocardial enzyme profile indexes [creatine kinase isoenzyme (CK-MB), troponin I(cTnI), lactate dehydrogenase (LDH)], major adverse cardiovascular events (MACE) and bleeding complications were compared between the two groups.【Results】After treatment, TIMI blood grading in both groups was significantly improved compared with that before surgery, and TIMI blood grading in the observation group was better than that in the control group, the difference was statistically significant (P<0.05). After treatment, serum CK-MB, cTnI and LDH levels in the 2 groups were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). After 3 months of follow-up, the incidence of MACE in the observation group was significantly lower than that in the control group, with statistical significance (P<0.05). No serious bleeding occurred in all patients during treatment, and there was no significant difference in the incidence of bleeding complications between the two groups (P>0.05).【Conclusion】The use of Tirofiban during perioperative PCI can effectively improve the coronary artery flow and myocardial injury in ACS patients, reduce the incidence of MACE, and do not increase the risk of bleeding.
2025, Vol. 42 
